LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Analyst Ratings
NYSEARCA:LCTX • US53566P1093
1.66 USD
-0.04 (-2.35%)
At close: Feb 13, 2026
1.66 USD
0 (0%)
After Hours: 2/13/2026, 8:21:26 PM
ChartMill assigns a Buy % Consensus number of 82% to LCTX. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 4.25. This target is 156.03% above the current price.
- LCTX was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LCTX.
- In the previous month the buy percentage consensus was at a similar level.
- LCTX was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-23 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-14 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-03-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | Maxim Group | Maintains | Buy -> Buy |
| 2025-01-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-18 | D. Boral Capital | Initiate | Buy |
| 2024-08-20 | Craig-Hallum | Initiate | Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-25 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-10 | HC Wainwright & Co. | Reiterate | Buy |
LINEAGE CELL THERAPEUTICS IN / LCTX FAQ
Can you provide the average price target for LINEAGE CELL THERAPEUTICS IN stock?
13 analysts have analysed LCTX and the average price target is 4.25 USD. This implies a price increase of 156.03% is expected in the next year compared to the current price of 1.66.
Can you provide the consensus rating for LINEAGE CELL THERAPEUTICS IN stock?
The consensus rating for LINEAGE CELL THERAPEUTICS IN (LCTX) is 81.5385 / 100 . This indicates that analysts generally have a positive outlook on the stock.